Regeneron Announces Upcoming 2016 Investor Conference Presentation
Get Alerts REGN Hot Sheet
Join SI Premium – FREE
TARRYTOWN, N.Y., Feb. 2, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the following investor conference:
- Leerink Partners 5th Annual Global Healthcare Conference at 8:30 a.m. Eastern Time on Thursday, February 11, 2016
The session may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page. Archived versions of the presentation will be available for 30 days.
About Regeneron Pharmaceuticals, Inc.Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Contact Information:
|
Investor Relations |
Corporate Communications |
|
Manisha Narasimhan, Ph.D. |
Hala Mirza |
|
914.847.5126 |
914.847.3422 |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-2016-investor-conference-presentation-300213556.html
SOURCE Regeneron Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron Pharma (REGN) PT Raised to $950 at JPMorgan
- Elis announces the results of the conversion and exchange period for its 2029 OCEANEs
- Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share